SCHEMBL31209652

SCHEMBL31209652

CC(C)(C)OC(=O)N1CC[C@@H](N2CC[C@H](O)C2)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.45
CHRM1 P11229 1/20 0.45
CHRM3 P20309 1/20 0.45
HPGD P15428 1/20 0.44
RECQL P46063 1/20 0.43
EPHX1 P07099 1/20 0.43
MAPT P10636 2/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
KMT2A Q03164 1/20 0.41
USP2 O75604 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
USP30 Q70CQ3 1/20 0.40
GPR119 Q8TDV5 3/20 0.40
CCNT1 O60563 1/20 0.40
CDK9 P50750 1/20 0.40
JAK2 O60674 1/20 0.40
JAK1 P23458 1/20 0.40
KDM4E B2RXH2 1/20 0.39
THRB P10828 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16321614 0.93 CHRM2 (0.46) CHRM2CHRM1CHRM3HPGDRECQL
SCHEMBL15017470 0.93 HPGD (0.49) CHRM2CHRM1CHRM3HPGDRECQL
SCHEMBL31209785 0.93 CHRM2 (0.46) CHRM2CHRM1CHRM3HPGDRECQL
SCHEMBL15017274 0.93 HPGD (0.49) CHRM2CHRM1CHRM3HPGDRECQL
SCHEMBL31208822 0.92 HPGD (0.46) CHRM2CHRM1CHRM3HPGDRECQL
SCHEMBL31209794 0.92 HPGD (0.46) CHRM2CHRM1CHRM3HPGDRECQL
SCHEMBL24582190 0.91 CHRM2 (0.47) CHRM2CHRM1CHRM3HPGDRECQL
SCHEMBL24583274 0.91 CHRM2 (0.47) CHRM2CHRM1CHRM3HPGDRECQL
SCHEMBL2673522 0.91 CHRM2 (0.47) CHRM2CHRM1CHRM3HPGDRECQL
SCHEMBL2673520 0.91 CHRM2 (0.47) CHRM2CHRM1CHRM3HPGDRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368193-A1 KRAS INHIBITORS ELI LILLY AND COMPANY 2024-11-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368193-A1 KRAS INHIBITORS KRAS, NRAS, HRAS CHRM2 4668/4885CHRM1 4532/4885CHRM3 4819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.